QTTB stock forecast, quote, news & analysis
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction... Show more
Q32 Bio (QTTB) Stock Analysis: Consolidating After the Alopecia Data Surge
Key Takeaways
- Q32 Bio (QTTB) shares have consolidated in the mid-teens after a sharp July 2026 rally that followed positive Phase 2a data for lead candidate bempikibart.
- The stock gained roughly 91% in a single session after 36-week SIGNAL-AA results showed meaningful hair regrowth in patients with severe alopecia areata.
- A $200 million follow-on equity offering and subsequent profit-taking pulled shares back from the July peak above $21 into a narrower range.
- Q32 Bio plans to advance bempikibart into a registration-directed program in the first half of 2027.
- Analyst consensus remains a Moderate Buy, with price targets well above recent trading levels but carrying substantial clinical-stage biotech risk.
Current Market Snapshot
Q32 Bio has been changing hands near $15 in recent trading, well below the intraday high above $23 reached in mid-July 2026 but far above its 52-week low of roughly $1.62. The stock's 52-week range reflects a dramatic re-rating: a micro-cap biotech that spent much of 2025 trading in the low single digits has re-emerged as a closely followed name after its alopecia areata program delivered encouraging clinical data. The current market capitalization is approximately $430 million.
Sentiment around QTTB has been shaped by two opposing forces. Positive trial results sharply improved the perceived odds of success for bempikibart, prompting multiple analysts to raise price targets. At the same time, a large equity raise and the inevitable pullback from a parabolic one-day move have kept shares range-bound. The stock now trades with a moderate short interest position and elevated trading volume relative to its historical average, consistent with active debate between bulls focused on the pipeline and investors mindful of dilution and execution risk.
Q32 Bio (QTTB) Business Overview and Competitive Position
Q32 Bio is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on restoring healthy immune balance in autoimmune and inflammatory diseases. Its lead program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody designed to block signaling through the IL-7 and TSLP pathways and re-regulate adaptive immune function. The company is developing the therapy primarily for alopecia areata, an autoimmune condition that causes patchy hair loss and affects roughly 700,000 people in the United States alone.
Bempikibart's positioning centers on offering a non-JAK alternative for patients with severe or very severe disease, including those who have previously been treated with oral JAK inhibitors. Q32 Bio is also advancing an earlier-stage complement-targeted platform aimed at tissue-specific inhibition for renal, ophthalmologic, and other complement-mediated indications. Investors follow the stock for its potential to deliver a differentiated, potentially safer and more durable treatment option in a market with significant unmet need, while weighing the execution and financing requirements typical of pre-commercial biotech.
Recent Developments Driving QTTB
The defining event of the period came on July 13, 2026, when Q32 Bio reported positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata. The study met its primary endpoint, with the modified intent-to-treat population recording a mean 35.3% reduction in Severity of Alopecia Tool (SALT) scores from baseline. At week 36, 40% of patients in that group achieved a SALT-20 response, corresponding to 80% or greater scalp hair coverage. Importantly, no treatment-related serious adverse events or Grade 3 or higher events were reported, and early follow-up suggested responses could persist after dosing ended.
The readout triggered a roughly 91% single-day gain, taking shares from a July 10 close of $11.21 to a July 13 close of $21.38. Wall Street responded quickly: Wells Fargo upgraded the stock to Overweight with a $66 target, while Oppenheimer and Mizuho raised their targets to $40 and $36, respectively, each citing improved odds of success for the program.
The rally was tempered by financing news. Q32 Bio announced a proposed $200 million public offering of common stock and pre-funded warrants to fund advancement of bempikibart into later-stage trials, introducing dilution pressure that contributed to the stock's retreat from its peak. Since then, shares have largely traded in a range between roughly $14.50 and $16.50 as investors absorb the offering and await the next clinical and regulatory milestones.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are currently drawing attention across the platform. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to filter and compare approaches that fit different objectives and risk tolerances. Reviewing the Trending AI Robots page can help investors identify automated strategies that are generating momentum, though past performance is not a guarantee of future results.
2026 Outlook and What Investors Should Watch
Looking ahead, Q32 Bio's investment narrative hinges on execution across several clinical and financial milestones. The company intends to initiate a registration-directed program for bempikibart in the first half of 2027, with full Part B results expected to be presented at an upcoming medical meeting. Investors will also monitor the ongoing week-52 off-drug follow-up data for further evidence of durability, a key differentiator the company is emphasizing relative to JAK inhibitors.
Financial positioning remains a central consideration. The $200 million offering strengthens the balance sheet for late-stage development, but additional capital may ultimately be required as the program advances toward pivotal trials. Regulatory interactions with the FDA, enrollment timelines for future studies, and the competitive landscape in alopecia areata will all influence sentiment. Broader biotech risk appetite and interest-rate expectations also play a role in how high-multiple, pre-revenue names like QTTB are valued. These factors, rather than any single data point, are likely to shape the stock's trajectory through the remainder of 2026 and into 2027.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for QTTB shows an upward move is likely
QTTB's Aroon Indicator triggered a bullish signal on August 31, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 185 similar instances where the Aroon Indicator showed a similar pattern. In of the 185 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTTB as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
QTTB moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QTTB crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.370) is normal, around the industry mean (20.363). P/E Ratio (3.823) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (3.313) is also within normal values, averaging (445.402).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology